Browse the evidence

High-protein provision (≥1.2 g/kg/day) combined with exercise therapy improves muscle mass and functional independence (ADL) in ICU survivors, but does not significantly improve quality of life (QoL) or mortality compared to standard care.

For ICU survivors, combining high protein intake (aiming for >1.2 g/kg/day) with early, structured exercise (including electrical stimulation if needed) can help preserve muscle and improve daily independence. However, this does not guarantee better quality of life or survival, and success depends heavily on actually delivering the prescribed protein, which is often difficult due to gut issues during critical illness.

Immersive Virtual Reality (IVR) cable resistance exergaming elicits muscle activation patterns and metabolic demands comparable to traditional resistance training while significantly reducing perceived exertion through dissociative attention.

If you struggle with resistance training because it feels too hard or boring, try an IVR system with adaptive resistance (like Black Box VR). It automatically adjusts weights to keep you near muscle failure, which builds strength and muscle effectively. The game environment distracts you from the fatigue, making high-intensity workouts feel more enjoyable and sustainable than traditional gym routines.

Successful long-term weight loss maintenance (≥5% loss sustained for ~4.5 years) significantly lowers serum total cholesterol compared to unsuccessful maintainers, but does not significantly improve triglycerides, LDL, HDL, fasting glucose, or HbA1c in the long term.

Maintaining significant weight loss (≥5%) for several years is associated with lower total cholesterol compared to regaining the weight. However, do not assume this will automatically fix your triglycerides, LDL, or blood sugar. Long-term maintenance alone may not be enough to normalize all cardiometabolic markers; ongoing monitoring and potentially other lifestyle or medical interventions are necessary for comprehensive heart health.

Trained individuals performing resistance training for hypertrophy often exceed recommended weekly set volumes for specific muscle groups, particularly upper body muscles in men and lower body muscles in women, leading to disproportionate training loads.

If you are training for muscle growth, check your weekly set counts. Men often overtrain upper body (chest/arms) while women overtrain lower body (glutes/legs). Aim for balance between muscle groups rather than maximizing volume on 'aesthetic' muscles, as excessive volume may not yield extra muscle and could increase injury risk. Follow evidence-based ranges (e.g., 10-20 sets per muscle per week) rather than arbitrary high numbers.

Time-Restricted Eating (TRE), defined as restricting daily energy intake to a window of ≤10 hours, reduces obesity, inflammation, and insulin resistance in humans independent of caloric restriction.

To try Time-Restricted Eating, compress your daily eating into a 10-hour window, such as 10 AM to 8 PM. You do not need to count calories or change what you eat, just when you eat it. Ensure your last meal is finished by 8 PM. This strategy has been shown to improve insulin resistance and reduce inflammation in adults, independent of how much total food is consumed.

Combining Duodenal Mucosal Ablation (DMR) or Electroporation (ReCET) with GLP-1 receptor agonists (like Liraglutide or Semaglutide) can enable a majority of insulin-requiring T2D patients to eliminate exogenous insulin.

If you have Type 2 Diabetes and require insulin, ask your doctor about combining endoscopic procedures (like DMR or ReCET) with GLP-1 medications (like Semaglutide or Liraglutide). This combination has shown high success rates (up to 86% in small studies) in helping patients stop taking insulin. While it involves both a procedure and medication, the goal is to achieve insulin independence and better long-term control. This approach is still emerging, so discuss the risks and benefits with a specialist.

Higher Body Mass Index (BMI) is significantly correlated with lower VO2 max in martial arts athletes, indicating that increased body mass is associated with reduced aerobic capacity.

For martial arts athletes, maintaining a healthy BMI is crucial for maximizing aerobic capacity (VO2 max). If your BMI is high, it may be limiting your endurance. Focus on nutritional periodization and body composition management to improve your VO2 max, which is a key determinant of performance in sports like Karate, Judo, and Kempo.

RYGB leads to a significant reduction in the use of antihypertensive and antidiabetic medications, even in patients who do not achieve total disease remission.

Even if surgery does not completely cure your diabetes or high blood pressure, it often allows you to significantly reduce or stop taking your medications. This reduces the burden of polypharmacy and potential side effects, improving overall metabolic health.

Intentional weight loss interventions (lifestyle, pharmacotherapy) are associated with improved cardiovascular outcomes, including reduced mortality and incidence of cardiovascular events, although the magnitude of benefit and specific effects on cardiovascular mortality remain controversial and dependent on the weight loss extent.

This paper is a protocol for a future study, so no specific advice can be given yet. However, it highlights that intentional weight loss through lifestyle changes (diet, exercise) or medication is generally recommended to improve heart health, despite conflicting evidence on whether it strictly reduces death rates from heart disease. Patients should consult guidelines for managing obesity to reduce cardiovascular risk factors like blood pressure and lipids.

Multidisciplinary weight management programs (WMPs) combining physician oversight, diet, exercise, and behavioral therapy are feasible and effective for obesity treatment in primary care, addressing the gap between patient need and current care models.

If you are struggling with obesity in primary care, ask your doctor about a multidisciplinary weight management program. These programs combine your doctor's oversight with a dietitian for nutrition, a behavioral health provider for coping strategies, and structured exercise. This team-based approach is more effective than trying to manage weight alone or with just a doctor's advice, especially if you are from a high-risk or lower-income background.

Adopting a high fat-to-energy ratio (FER) and low carbohydrate-to-energy ratio (CER) diet over the course of adult life significantly increases the risk of obesity, diabetes, and all-cause mortality.

If you are changing your diet to eat more fat and fewer carbohydrates over time, be aware that this specific shift (high fat, low carb) has been linked to higher risks of obesity, diabetes, and death in long-term studies of Chinese adults. Conversely, maintaining a lower fat intake with higher carbohydrates did not show these increased risks after accounting for social factors. Focus on the overall pattern of your diet over years, not just single meals.

Preoperative optimization with GLP-1 agonists (specifically semaglutide 2.4 mg/week) enables patients with severe obesity (BMI ≥ 35 kg/m²) to achieve target BMI ≤ 35 kg/m², making them eligible for complex abdominal wall repair.

If you have severe obesity and need complex abdominal wall surgery, standard diet and exercise often fail to lower your BMI enough for safe surgery. Using GLP-1 agonists (like semaglutide) for about 8 months can help you lose enough weight (average 11.3%) to meet the safety threshold (BMI ≤ 35) for the procedure. This makes you eligible for surgery that might otherwise be denied or deemed too risky.

In adults with Type 1 Diabetes (T1D) and obesity (BMI ≥27 kg/m²), 12 months of treatment with GLP-1 receptor agonists (tirzepatide, semaglutide, or liraglutide) produces significant weight loss (7.1%–10.9%) without increasing the risk of severe hypoglycemia or diabetic ketoacidosis (DKA).

If you have Type 1 Diabetes and obesity, GLP-1 based medications (tirzepatide, semaglutide, or liraglutide) can help you lose significant weight (7-11%) over a year without increasing your risk of dangerous low blood sugar or DKA, provided your insulin regimen is stable. These drugs also modestly improve blood sugar control and reduce insulin needs.

Among GLP-1/GIP agonists used in Type 1 Diabetes, tirzepatide produces significantly greater weight loss (10.9%) compared to semaglutide (9.9%) and liraglutide (7.1%).

If you have Type 1 Diabetes and obesity, tirzepatide appears to offer the highest weight loss potential (approx. 11%) compared to semaglutide (approx. 10%) and liraglutide (approx. 7%) over 12 months, though all are effective.

GLP-1/GIP agonists reduce daily insulin requirements in Type 1 Diabetes patients by 8.3 to 11.4 units per day over 12 months, likely due to reduced insulin resistance.

Starting GLP-1/GIP agonists in T1D allows you to lower your daily insulin dose by approximately 8-11 units, which may help manage weight and insulin resistance without increasing hypoglycemia risk.

Self-reported increases in sweet and salty taste perception during GLP-1 or dual GIP/GLP-1 receptor agonist therapy are significantly associated with increased satiety, reduced appetite, and reduced food craving.

If you are taking a GLP-1 medication and notice your taste has changed (e.g., sweets taste stronger or saltier), this is a common and potentially helpful side effect. The research suggests these sensory changes are linked to feeling fuller faster and having fewer cravings, which supports your weight loss efforts. Do not be alarmed by these changes; they may be part of how the medication helps regulate your appetite.

Reducing the dosing frequency of GLP-1 receptor agonists (semaglutide and tirzepatide) after initial weight loss maintenance preserves a significant proportion of weight loss efficacy compared to once-weekly dosing, making it a viable strategy for long-term weight maintenance.

If you are maintaining weight loss on a GLP-1 agonist (like semaglutide or tirzepatide) and face supply issues or high costs, discuss extending the dosing interval with your provider. Instead of stopping completely, moving from weekly to every 10-14 days (or even 28 days for some) can maintain a significant portion of your weight loss (e.g., 50-70%) while saving money and extending supply. This is not a substitute for lifestyle changes but a viable maintenance strategy.

Initiating anti-obesity medications (AOMs) more than 12 months after bariatric surgery is associated with a significantly lower risk of adverse events compared to initiating them within the first 12 months.

If you are considering weight loss medication after bariatric surgery, current evidence suggests that waiting until at least 12 months post-surgery to start the medication is associated with a significantly lower risk of adverse events compared to starting within the first year. This may allow for better surgical recovery before adding pharmacological stress.

GLP-1 agonists (Liraglutide and Semaglutide) are promising interventions for reducing antipsychotic-induced weight gain, with Semaglutide showing superior efficacy to Liraglutide in general obesity populations, though evidence in SMI is still emerging.

GLP-1 medications like Liraglutide and Semaglutide show strong promise for counteracting weight gain from antipsychotics. Liraglutide has shown significant weight loss in SMI patients, and Semaglutide appears even more effective in general obesity studies. However, these require injections, which can be difficult for some patients, and more large-scale studies are needed to confirm long-term safety and efficacy in this specific group.

In patients with mild to moderate Parkinson's disease, protein intake below 1 g/kg/day is independently associated with positive sarcopenia screening, higher fat mass index, and lower relative skeletal muscle index.

If you have mild to moderate Parkinson's, ensure you are eating at least 1 gram of protein per kilogram of body weight daily. This study links lower intake to loss of muscle strength and increased body fat. Talk to your doctor about timing your protein intake around your medication to maximize both drug effectiveness and muscle health.

National-level powerlifters consume high levels of sports supplements (specifically creatine monohydrate, caffeine, and whey protein) primarily to enhance performance and mitigate dietary deficits, yet often lack structured timing or professional guidance.

If you are a competitive powerlifter, you are likely using supplements like creatine and caffeine. Ensure you are buying from reputable sources to avoid contamination risks, as internet purchases carry higher dangers of adulteration. While your protein intake may be sufficient, supplements are often used for performance; prioritize evidence-based options like creatine and caffeine over unproven compounds.

Adult-onset obesity (developing after high school graduation) is associated with greater success in weight loss interventions compared to childhood-onset obesity.

If you developed obesity in adulthood, you may have a better chance of successful weight loss through behavioral programs compared to those who were obese since childhood. This highlights the importance of early intervention and consistent adherence to dietary and exercise goals.

Personalized behavioral weight loss (PBWL) involving a 4-week experimentation phase with continuous glucose monitoring (CGM) yields significantly greater 12-week weight loss than standard behavioral weight loss (BWL) with fixed prescriptions.

Instead of sticking to one diet, try a 4-week 'experiment' phase. Use a continuous glucose monitor (CGM) to test different macronutrient ratios (low-carb vs. low-fat) and meal frequencies (3 meals vs. snacks). Track how your blood sugar and hunger respond to each. After 4 weeks, pick the combination that gave you the best glucose control and felt most sustainable, then stick with it for the next 8 weeks. This personalized approach led to nearly double the weight loss of standard dieting in this study.

Maintaining previous resistance training volume yields superior maximum strength gains compared to increasing volume by 30% or 60% in trained males, while muscle hypertrophy remains equivalent across all volume levels.

If you are a trained lifter, do not automatically increase your weekly set count when you feel stuck. This study suggests that simply maintaining your current effective volume may yield better maximum strength gains than increasing it by 30-60%. However, if your goal is strength endurance (reps at submaximal loads), a moderate 30% volume increase may be beneficial. Monitor your recovery and prioritize technique over arbitrary volume increases.